Etomethazene (5-methyldesnitroetonitazene, 5-methyl etodesnitazene, Eto) is a benzimidazole derivative with opioid effects which has been sold as a designer drug over the internet since 2022, first being definitively identified in Sweden in January 2023.

[1][2] It is an analogue of etonitazene where the nitro (NO2) group has been replaced by a methyl (CH3) group.

While formal studies into its pharmacology have yet to be carried out, it showed far less potency than etonitazene itself.

Etomethazene has an analgesic potency around 20 times that of morphine with a relatively short duration of about 120 min.

This analgesic-related article is a stub.